StockData
Vireo Growth Inc. logo

Vireo Growth Inc. (VREOF) company profile

VREOFOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/30
$9.01+0.01 (+0.11%)

Close on Oct 19, 2026Market cap $406.23MP/E –Yield –

About Vireo Growth

Pharmaceutical Preparations, SIC 2834

Vireo Growth Inc. is a vertically integrated cannabis company that cultivates, manufactures, wholesales, and retails cannabis products. Its operations span three primary divisions: cultivation, production, and retail dispensaries. The company produces and packages cannabis items across multiple formats, including inhalables such as flower, concentrates, and vaporizers; ingestibles such as edibles, tablets, and tinctures; and topicals. Vireo Growth serves medical patients and adult-use consumers through its retail stores, while also supplying third-party licensed dispensaries through wholesale channels.

The company operates in six American states: Maryland, Minnesota, Missouri, Nevada, New York, and Utah. Its footprint includes 36 retail dispensaries along with dedicated cultivation and manufacturing facilities. The business employs over six hundred workers. Vireo Growth maintains its corporate headquarters in Minneapolis, Minnesota, and a registered office in Vancouver, British Columbia.

Summary of the business section of Vireo Growth's latest annual report, written by StockData.

Company profile

Company

Legal name
Vireo Growth Inc.
Founded
2014
Headquarters
Minneapolis, MN
Address
207 South 9th Street 55402
Phone
(612) 999-1606
Employees
612, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
A1
Fiscal year ends
December 31
Auditor
DAVIDSON & COMPANY LLP, Vancouver, BC

Stock & identifiers

Ticker
VREOF
Exchange
OTC
IPO date
Mar 22, 2019
Shares outstanding
48M, Aug 14, 2026
Public float
$345.97M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-30 reverse, Jun 5, 2026
SEC CIK
1771706
CUSIP
38238W103
ISIN
CA38238W1032
FIGI
BBG00NPL59T9
Share class FIGI
BBG001SNXQB0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John MazarakisChief Executive Officer, Director9,833,737
Kyle Eugene KingsleyCo-Executive Chairman, Director14,206,363
Joseph DuxburyChief Accounting Officer136,333
Sean Michael ApfelbaumGC and Corporate Secretary271,188
Amber Holly ShimpaPresident1,119,965
Tyson MacdonaldChief Financial Officer7,416,021
Michael L. SteinerDirector1,675,903
Christopher HagedornDirector0
Judd Theodore NordquistDirector118,912
Victor E. ManceboDirector118,912
Ross Michael HusseyDirector33,170

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsTotalvs. prior year
John Mazarakis
Chief Executive Officer and Co-Executive Chairman
$1$2.30M$17.73M$20.03M+2404%
Tyson Macdonald
Chief Financial Officer
$500.00K$1.15M$8.62M$10.27M+1160%
Sean Apfelbaum
General Counsel
$145.83K$300.00K$128.80K$574.63K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of February 6, 2026 we had 612 employees, 520 of whom were full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 9, 2026MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 26, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 13, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 9, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 6, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 25, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 14, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 12, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 6, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 6, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 12, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 12, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 23, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 24, 2024Name changeName changed from Goodness Growth Holdings, Inc. to Vireo Growth Inc.
Apr 2, 2024DeregistrationTermination of SEC registration (Form 15)
May 14, 2021Name changeName changed from Vireo Health International, Inc. to Goodness Growth Holdings, Inc.

See a number that looks wrong?